What Is MOTS-c? What the Research Actually Shows

What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in the mitochondrial DNA (mtDNA) 12S rRNA region. Discovered in 2015, it is studied as a possible signal linking mitochondrial and metabolic stress with cellular responses. Evidence includes cultured-cell experiments, mouse studies, and human measurements of endogenous MOTS-c; it does not yet establish a treatment benefit, safety profile, or exercise replacement in people.

The basic definition: a peptide from mitochondrial DNA

MOTS-c is unusual because of both its size and its origin. It is a short peptide made up of 16 amino acids, rather than a large protein. The original report identified its coding sequence in a short open reading frame, or ORF, within the mitochondrial 12S ribosomal-RNA region of mtDNA. In other words, the sequence sits in a part of the mitochondrial genome traditionally discussed in connection with ribosomal RNA, yet it can also give rise to a small peptide.[1]

That origin makes MOTS-c a member of the mitochondrial-derived peptide research field. Mitochondria are not only cellular structures involved in energy production; they also respond to changing nutrient and stress conditions. A peptide encoded by mitochondrial DNA could, in principle, help communicate that state to the rest of the cell. “Could” matters here. The genomic origin identifies what MOTS-c is; it does not, by itself, prove what it does in a person or whether changing its amount would improve health.

The name is therefore more precise than many short marketing descriptions. MOTS-c is not NAD+, not a vitamin, and not synonymous with exercise. NAD+ is a cellular coenzyme, whereas MOTS-c is a peptide signal candidate. Their appearance in the same longevity conversations reflects overlapping interest in metabolism, not interchangeable biology. For that distinction, see the NAD+ versus MOTS-c comparison.

What the 2015 discovery study reported

Lee and colleagues reported MOTS-c in 2015 as part of a search for biologically active peptides encoded by the mitochondrial genome. Their paper connected the 16-amino-acid sequence with metabolic homeostasis and then tested the idea in cultured cells and mice. The study is foundational because it supplied the sequence, a biological context, and experiments that made MOTS-c a testable research subject rather than merely a computational prediction.[1]

In the cultured-cell work, the authors linked MOTS-c activity to folate-cycle and purine-biosynthesis pathways and to AMPK-related signaling. In the mouse experiments, administered MOTS-c prevented diet- and age-associated insulin resistance and reduced or prevented obesity-related findings under the conditions tested. Those are important preclinical observations, but the categories must remain separate: a result in a mouse receiving an administered peptide is not a result in a human patient, and a cellular pathway is not a clinical outcome.

The discovery paper consequently supports several modest conclusions. MOTS-c has a defined mitochondrial sequence; cells can respond to it under experimental conditions; and mouse metabolism can change in the reported models. It does not support the stronger conclusion that MOTS-c prevents obesity or insulin resistance in people. It also does not settle how endogenous MOTS-c is made, released, measured, or regulated in every human tissue.

Proposed mechanisms: folate, purines, and AMPK

A mechanism is an explanation for how an observation might occur, not a substitute for an outcome study. The first MOTS-c report proposed a connection with the folate cycle and purine biosynthesis. These pathways help cells manage one-carbon chemistry and nucleotide production. The paper also associated MOTS-c with AMP-activated protein kinase, or AMPK, a nutrient- and energy-sensitive signaling system. This gave researchers a plausible way to investigate how a small mitochondrial peptide might influence metabolic stress responses.[1]

AMPK is best treated here as a signaling observation and research hypothesis. Finding AMPK-dependent effects in cells does not mean that every change in AMPK is beneficial, that the same effect occurs in people, or that an intervention will reproduce the broad effects of exercise. The pathway can help explain an experiment while leaving the clinically important questions unanswered: which tissue responds, at what physiological state, for how long, and with what meaningful consequence?

A second line of work examined where MOTS-c goes during metabolic stress. Kim and colleagues reported in cultured cells that MOTS-c translocated to the nucleus in response to metabolic stress in an AMPK-dependent manner. They also reported an interaction with NRF2 and regulation of genes associated with antioxidant-response elements. This is evidence of a stress-responsive cellular signaling model, not evidence from a clinical trial.[2]

The nucleus finding is scientifically interesting because it suggests that a mitochondrial-encoded peptide might influence nuclear gene expression. Mitochondria and the nucleus would then be connected not only through metabolites and established signaling pathways, but also through a small peptide whose location changes with cellular conditions. Yet “nuclear translocation” should not be translated into “protects people from disease.” It describes an observed laboratory process; its relevance to human health still requires careful validation.

What the evidence actually shows

The cleanest way to read MOTS-c research is to separate three evidence levels. Laboratory experiments can test molecular pathways and cell responses. Animal experiments can test physiology in a whole organism under controlled conditions. Human studies can measure endogenous peptide patterns or test an intervention in people. These levels complement one another, but they do not answer the same question and should not be collapsed into one headline.

Laboratory evidence

Cultured cells have been used to study the proposed folate-cycle, purine, and AMPK connections, as well as movement of MOTS-c into the nucleus during metabolic stress. Cultured muscle cells also appear in the exercise-related research. These models are useful because researchers can control conditions and look closely at pathways. They cannot reproduce an entire human organism, including absorption, distribution, clearance, immune responses, tissue interactions, or the effects of an existing disease.

Mouse evidence

The 2015 work reported metabolic findings in mice, including prevention of diet- and age-associated insulin resistance under the study conditions.[1] Reynolds and colleagues later reported performance-related results after administering MOTS-c to young, middle-aged, and old mice, alongside experiments in cultured muscle cells.[3] This pattern can motivate further research into mitochondrial signaling and physical decline. It cannot establish that administered MOTS-c improves performance, insulin sensitivity, body composition, or longevity in humans.

Human evidence

The human component of the Reynolds study was different from its mouse intervention. The researchers reported that endogenous MOTS-c in skeletal muscle and plasma rose after exercise in a small group of healthy young men. That is a human exercise-physiology observation: it concerns peptide levels made or present in the body in that context. It is not a trial in which people received MOTS-c, and it does not show that administering MOTS-c reproduces exercise or improves a human outcome.[3]

This distinction also explains why “human study” can be a misleading shorthand. Human-derived cultured cells are not human participants. Human blood or muscle measurements are not necessarily intervention evidence. A registered intervention is not a completed trial result. Each description says something different about the evidence and must be reported as such.

The verified trial record

As checked in the live ClinicalTrials.gov record on September 12, 2026, NCT07505745 was listed as recruiting, with no posted results. Its official title is A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity.[4]

This record matters because it shows that interventional human research is being registered and recruited. It does not provide efficacy, safety, or pharmacodynamic results. A registry entry primarily describes a planned or ongoing study, and sponsor-reported registration is not independent approval or proof that an intervention works or is safe. The responsible statement is therefore not “there have been no human studies.” Human physiology studies and a recruiting intervention record exist. The responsible statement is that, at the evidence check, no results were posted from this registered trial.

What remains uncertain

Several uncertainties sit between an intriguing mechanism and a useful human conclusion. Researchers still need reproducible ways to measure endogenous MOTS-c across tissues and laboratories, a clearer account of when it is produced and released, and a better understanding of how age, exercise, metabolic state, and disease affect those measurements. They also need to determine whether observations in cells and mice translate to people, rather than assuming that they do.

Human intervention studies must answer questions that a mechanism cannot: what outcomes change, in whom, for how long, and with what adverse effects. A change in a blood concentration, an AMPK signal, an antioxidant-response gene, or a mouse performance measure is not automatically a meaningful human benefit. Until reported trials address those questions, MOTS-c is best described as an early-stage research topic with compelling biology and incomplete clinical evidence.

That conclusion is neither a dismissal nor an endorsement. It keeps the evidence proportional to the claim. MOTS-c may help researchers understand communication between mitochondria and the nucleus, but current sources do not justify a dose, route, protocol, treatment recommendation, or efficacy claim for humans.

Five questions readers often ask

Read the evidence in context

For a broader, source-led discussion of the two molecules, see NAD+ vs MOTS-c: The Honest Comparison. It keeps mitochondrial signaling, NAD+ biology, and the difference between preclinical and human evidence in the same frame without turning an unresolved research question into a personal protocol.

Related reading: NAD+ vs MOTS-c · MOTS-c and exercise · The human evidence for MOTS-c · all articles